Advancing diagnosis and early risk assessment of preeclampsia through noninvasive cell-free DNA methylation profiling.

ABSTRACT:

Background

Aberrant embryo implantation and suboptimal placentation can lead to (severe) complications such as preeclampsia and fetal growth restriction later in pregnancy. Current identification of high-risk pregnancies relies on a combination of risk factors, biomarkers, and ultrasound examinations, a relatively inaccurate approach. Previously, aberrant DNA methylation due to placental hypoxia has been identified as a potential marker of placental insufficiency and, hence, potential (future) pregnancy complications. The goal of the Early Prediction of prEgnancy Complications Testing, or the ExPECT study, is to validate a genome-wide, cell-free DNA (cfDNA) methylation strategy to diagnose preeclampsia accurately. More importantly, the predictive potential of this strategy is also

SUBMITTER: Baetens M 

PROVIDER: S-EPMC11656954 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature